Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3632704 | 0.94 | FFAR1 (0.37) | FFAR1FFAR4MAPTLMNANPSR1 | |
| SCHEMBL3623821 | 0.90 | FFAR1 (0.40) | FFAR1FFAR4MAPTLMNANPSR1 | |
| SCHEMBL3628504 | 0.89 | FFAR1 (0.41) | FFAR1FFAR4MAPTLMNANPSR1 | |
| SCHEMBL3624351 | 0.88 | FFAR1 (0.42) | FFAR1FFAR4DRD4ADRA1DDRD3 | |
| SCHEMBL3633254 | 0.87 | MAPT (0.33) | MAPTLMNANPSR1POLB | |
| SCHEMBL3630289 | 0.86 | FFAR1 (0.44) | FFAR1FFAR4NPSR1 | |
| SCHEMBL3633264 | 0.86 | FFAR1 (0.41) | FFAR1FFAR4MAPTDRD4ADRA1D | |
| SCHEMBL3630380 | 0.83 | FFAR1 (0.45) | FFAR1FFAR4NPSR1DRD4ADRA1D | |
| SCHEMBL3629227 | 0.83 | FFAR1 (0.39) | FFAR1FFAR4MAPTLMNANPSR1 | |
| SCHEMBL3631312 | 0.83 | FFAR1 (0.49) | FFAR1FFAR4MAPTNPSR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786165-B2 | Aminophenylpropanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786165-B2 | Aminophenylpropanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1726580-A1 | AMINOPHENYLPROPANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | GPR119, GPR55, GPR65 | FFAR1 5/4885FFAR4 18/4885MAPT 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.